SciSparc Ltd.

NASDAQ
SPRC
paper.types.company
Rentabilité sur six mois: -35.3%
Rendement en dividendes: 0%
Secteur: Healthcare

Calendrier des promotions SciSparc Ltd.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise SciSparc Ltd.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and epilepsy and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form.

plus de détails
It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation, as well as a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. The company was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-08-30
ISIN
IL0010951403
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 3.86 4
P/BV 0.5641 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -58.38 0
ROE -79.71 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0066 10
Debt/Ratio 0.0044 10
Debt/Equity 0.0056 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 137.45 10
Rentabilité Ebitda, % 168.23 10
Rentabilité EPS, % -95.61 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.321 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 0.3305 $ 0.321 $ 0.3244 $ -2.87 % 0 % 0 %
common.calendar.number_days.30d 0.3075 $ 0.2947 $ 0.3399 $ 4.39 % 0 % 0 %
common.calendar.number_days.90d 0.2837 $ 0.2705 $ 0.4 $ 13.15 % 0 % 0 %
common.calendar.number_days.180d 0.4961 $ 0.2133 $ 1.07 $ -35.3 % 0 % 0 %
common.calendar.number_days.1y 0.424 $ 0.208 $ 1.07 $ -24.29 % 0 % 0 %
common.calendar.number_days.3y 1.02 $ 0.208 $ 139.93 $ -68.53 % 0 % 0 %
common.calendar.number_days.5y 0 $ 0.208 $ 139.93 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.208 $ 139.93 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 0.4987 $ 0.2705 $ 1.07 $ -35.63 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Itschak Shrem President & Director 219k 1947 (78 années)
Dr. Adi Zuloff-Shani Ph.D. Chief Technologies Officer 274k 1969 (56 années)

Informations sur l'entreprise

Adresse: Israel, Tel Aviv, Tower A - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://scisparc.com